Feng Jiang

US Patent:

20070178503, Aug 2, 2007

Filed:

Dec 19, 2006

Appl. No.:

11/641008

Inventors:

Feng Jiang - Ellicott City MD, US

International Classification:

C12Q 1/68
C12M 1/34

US Classification:

435006000, 435287200

Abstract:

An in situ genomic DNA chip can be used directly on clinical specimens in situ for detecting, diagnosing and/or predicting diseases, especially diseases characterized by a genetic aberration such as cancers, by simultaneous detection of one or more unique genetic aberrations using one or more multiple specific probes. The present invention offers high sensitivity for detection of such genetic aberrations and, further, has substantial implications for large-scale population-based molecular epidemiologic studies and therapeutic interventions.

US Patent:

20210108269, Apr 15, 2021

Filed:

Apr 5, 2018

Appl. No.:

16/603061

Inventors:

- BALTIMORE MD, US
- WASHINGTON DC, US
Feng Jiang - Ellicott City MD, US

International Classification:

C12Q 1/6886
C12Q 1/686

Abstract:

The present invention provides a method of predicting whether a pulmonary nodule in a subject is benign or non-small cell lung cancer, comprising obtaining the results of an assay that measures an expression level of miR205-5p in a plasma sample from the subject; obtaining the results of an assay that measures an expression level of miR126 in a plasma sample from the subject; obtaining the results of an assay that provides a size of the pulmonary nodule in the subject; and calculating a probability value based on the combination of the expression levels of miR205-5p and miR126, and the size of the pulmonary nodule, wherein if the probability value exceeds a specified threshold, the pulmonary nodule is predicted as non-small cell lung cancer.

US Patent:

20180074059, Mar 15, 2018

Filed:

Sep 14, 2017

Appl. No.:

15/704828

Inventors:

Feng Jiang - Ellicott City MD, US

Assignee:

University of Maryland, Baltimore - Baltimore MD
The United States of America as Represented by the Department of Veterans Affairs - Washington DC

International Classification:

G01N 33/574
C12N 15/113

Abstract:

Provided herein are methods for non-invasively diagnosing and/or prognosing a lung cancer and for determining the efficacy of a therapeutic treatment regimen for the lung cancer. Expression levels of at least two small non-coding RNAs, for example, microRNAs and small nucleolar RNAs, are measured and used to calculate an area under the curve (AUC) that provides a probability of lung cancer in the subject. The smoking history of the subject and, if present, the size of pulmonary nodules may be incorporated into the calculation.